These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 1448843)

  • 1. Pattern of 6-mercaptopurine urinary excretion in children with acute lymphoblastic leukemia: urinary assays as a measure of drug compliance.
    Macdougall LG; McElligott SE; Ross E; Greeff MC; Poole JE
    Ther Drug Monit; 1992 Oct; 14(5):371-5. PubMed ID: 1448843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The circadian schedule for childhood acute lymphoblastic leukemia maintenance therapy does not influence event-free survival in the NOPHO ALL92 protocol.
    Clemmensen KK; Christensen RH; Shabaneh DN; Harila-Saari A; Heyman M; Jonsson OG; Wesenberg F; Rosthøj S; Schmiegelow K;
    Pediatr Blood Cancer; 2014 Apr; 61(4):653-8. PubMed ID: 24265159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of morning versus evening schedule for oral methotrexate and 6-mercaptopurine on relapse risk for children with acute lymphoblastic leukemia. Nordic Society for Pediatric Hematology and Oncology (NOPHO).
    Schmiegelow K; Glomstein A; Kristinsson J; Salmi T; Schrøder H; Björk O
    J Pediatr Hematol Oncol; 1997; 19(2):102-9. PubMed ID: 9149738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia.
    Relling MV; Hancock ML; Boyett JM; Pui CH; Evans WE
    Blood; 1999 May; 93(9):2817-23. PubMed ID: 10216075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 6-mercaptopurine dosage and pharmacokinetics influence the degree of bone marrow toxicity following high-dose methotrexate in children with acute lymphoblastic leukemia.
    Schmiegelow K; Bretton-Meyer U
    Leukemia; 2001 Jan; 15(1):74-9. PubMed ID: 11243403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myelotoxicity, pharmacokinetics, and relapse rate with methotrexate/6-mercaptopurine maintenance therapy of childhood acute lymphoblastic leukemia.
    Schmiegelow K; Ifversen M
    Pediatr Hematol Oncol; 1996; 13(5):433-41. PubMed ID: 10897815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects on transmethylation by high-dose 6-mercaptopurine and methotrexate infusions during consolidation treatment of acute lymphoblastic leukemia.
    Keuzenkamp-Jansen CW; De Abreu RA; Blom HJ; Bökkerink JP; Trijbels JM
    Biochem Pharmacol; 1996 May; 51(9):1165-71. PubMed ID: 8645339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diurnal variation in the pharmacokinetics and myelotoxicity of mercaptopurine in children with acute lymphocytic leukemia.
    Koren G; Langevin AM; Olivieri N; Giesbrecht E; Zipursky A; Greenberg M
    Am J Dis Child; 1990 Oct; 144(10):1135-7. PubMed ID: 2403095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of tablet and liquid formulations of oral 6-mercaptopurine in children with acute lymphoblastic leukemia.
    Larsen RH; Hjalgrim LL; Grell K; Kristensen K; Pedersen LG; Brünner ED; Als-Nielsen B; Schmiegelow K; Nersting J
    Cancer Chemother Pharmacol; 2020 Jul; 86(1):25-32. PubMed ID: 32519032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Compliance with oral chemotherapy in childhood lymphoblastic leukaemia.
    Davies HA; Lilleyman JS
    Cancer Treat Rev; 1995 Mar; 21(2):93-103. PubMed ID: 7758006
    [No Abstract]   [Full Text] [Related]  

  • 11. 6-Thioguanine nucleotide accumulation in red blood cells during maintenance chemotherapy for childhood acute lymphoblastic leukemia, and its relation to leukopenia.
    Schmiegelow K; Bruunshuus I
    Cancer Chemother Pharmacol; 1990; 26(4):288-92. PubMed ID: 2369793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of methotrexate and 6-mercaptopurine dosage during maintenance chemotherapy for childhood acute lymphoblastic leukemia.
    Schmiegelow K
    Pediatr Hematol Oncol; 1991; 8(4):301-12. PubMed ID: 1782110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronopharmacokinetics of oral methotrexate and 6-mercaptopurine: is there diurnal variation in the disposition of antileukemic therapy?
    Balis FM; Jeffries SL; Lange B; Murphy RF; Doherty KM; Arndt CA; Luery N; Poplack DG
    Am J Pediatr Hematol Oncol; 1989; 11(3):324-6. PubMed ID: 2782561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Individual prediction of nonadherence to oral mercaptopurine in children with acute lymphoblastic leukemia: Results from COG AALL03N1.
    Hoppmann AL; Chen Y; Landier W; Hageman L; Evans WE; Wong FL; Relling MV; Bhatia S
    Cancer; 2021 Oct; 127(20):3832-3839. PubMed ID: 34161608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe Recurrent Nocturnal Hypoglycemia During Chemotherapy With 6-mercaptopurine in 2 Children With Acute Lymphoblastic Leukemia.
    Albiroty K; Al Sabahi A
    J Pediatr Hematol Oncol; 2023 Apr; 45(3):162-163. PubMed ID: 36706266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II trial of continuous-infusion 6-mercaptopurine for childhood leukemia.
    Adamson PC; Zimm S; Ragab AH; Balis F; Steinberg SM; Kamen BA; Vietti TJ; Gillespie A; Poplack DG
    Cancer Chemother Pharmacol; 1992; 30(2):155-7. PubMed ID: 1600597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose mercaptopurine followed by intermediate-dose cytarabine in relapsed acute leukemia.
    Lockhart S; Plunkett W; Jeha S; Ramirez I; Zipf T; Cork A; Pinkel D
    J Clin Oncol; 1994 Mar; 12(3):587-95. PubMed ID: 8120558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mercaptopurine metabolite levels are predictors of bone marrow toxicity following high-dose methotrexate therapy of childhood acute lymphoblastic leukaemia.
    Vang SI; Schmiegelow K; Frandsen T; Rosthøj S; Nersting J
    Cancer Chemother Pharmacol; 2015 May; 75(5):1089-93. PubMed ID: 25788208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maintenance Treatment With Low-Dose Mercaptopurine in Combination With Allopurinol in Children With Acute Lymphoblastic Leukemia and Mercaptopurine-Induced Pancreatitis.
    Zerra P; Bergsagel J; Keller FG; Lew G; Pauly M
    Pediatr Blood Cancer; 2016 Apr; 63(4):712-5. PubMed ID: 26878433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circadian time-dependent response of childhood lymphoblastic leukemia to chemotherapy: a long-term follow-up study of survival.
    Rivard GE; Infante-Rivard C; Dresse MF; Leclerc JM; Champagne J
    Chronobiol Int; 1993 Jun; 10(3):201-4. PubMed ID: 8319318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.